VCG
VRTX icon

Vantage Consulting Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Vantage Consulting Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-488
Closed -$229K – 176
2024
Q2 		$229K Sell
488
-88
-15% -$38.2K 0.17% 148
2024
Q1 		$241K Sell
576
-90
-14% -$38K 0.15% 139
2023
Q4 		$271K Sell
666
-12
-2% -$4.43K 0.18% 96
2023
Q3 		$236K Sell
678
-12
-2% -$4.2K 0.16% 128
2023
Q2 		$243K Sell
690
-145
-17% -$48.9K 0.14% 140
2023
Q1 		$263K Buy
835
+63
+8% +$18.9K 0.15% 126
2022
Q4 		$223K Sell
772
-103
-12% -$31.4K 0.13% 166
2022
Q3 		$253K Sell
875
-70
-7% -$20.1K 0.15% 106
2022
Q2 		$266K Sell
945
-27
-3% -$7.23K 0.15% 99
2022
Q1 		$254K Sell
972
-280
-22% -$66.5K 0.1% 132
2021
Q4 		$275K Sell
1,252
-40
-3% -$7.78K 0.07% 145
2021
Q3 		$234K Buy
1,292
+115
+10% +$22.5K 0.05% 158
2021
Q2 		$237K Buy
+1,177
New +$246K 0.04% 151
2021
Q1 		– Sell
-322
Closed -$76K – 1546
2020
Q4 		$76K Buy
+322
New +$73.9K 0.01% 271

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Vantage Consulting Group's VRTX Position: Q3 2024 in Review

Vantage Consulting Group sold out of Vertex Pharmaceuticals (VRTX) in Q3 2024, closing a stake of 488 shares — an estimated $229K sold.

Vantage Consulting Group first reported a position in VRTX in Q4 2020 and held it in 14 quarters. The position peaked at $275K in Q4 2021. 1,547 funds tracked by Wall St. Rank hold VRTX as of Q3 2024.

  • Vantage Consulting Group reported no remaining Vertex Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Vantage Consulting Group sold 488 Vertex Pharmaceuticals shares in Q3 2024, an estimated $229K.
  • Vantage Consulting Group first reported a position in Vertex Pharmaceuticals in Q4 2020 and held it in 14 quarters.
  • Vantage Consulting Group's Vertex Pharmaceuticals position peaked at $275K in Q4 2021.
  • 1,547 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2024.

Based on Vantage Consulting Group's 13F filing for Q3 2024, filed 14 Nov 2024.